Navigation Links
FSU researcher's 'mutant' proteins could lead to new treatment for heart disease
Date:3/24/2008

TALLAHASSEE, Fla. -- Heart damage due to blocked arteries remains the leading cause of disease and death in the Western world, but a Florida State University College of Medicine researcher is helping to open new pathways toward treating the problem.

Michael Blaber, a professor in the department of biomedical sciences, is researching mutant forms of a human protein that have been shown to help the human body grow new blood vessels to restore blood flow in damaged areas of the heart.

Working with a $264,000, three-year grant from the American Heart Association, Blaber hopes to provide data that will enable the use of the mutant proteins in new treatment methods previously unavailable for patients with advanced no option heart disease.

This research offers the potential to treat people who currently are being sent home to die, Blaber said. Weve tested a group of mutants in the laboratory with unusual properties of increased stability and activities -- good properties. In some cases it was unexpected, but the results are very promising.

Obstructed blood vessels and clogged or blocked arteries typically are treated through angioplasty, the mechanical widening of a vessel, or bypass surgery. Some patients, however, have numerous small blockages that cannot be treated through traditional approaches. In most cases, they are sent home with a predicted life expectancy that, no matter how its phrased, sounds like a death sentence.

A new approach to the problem called therapeutic coronary angiogenesis is creating hope through the injection of human fibroblast growth factor protein into affected areas. Improvements with the procedure may arise from the use of mutant forms with increased stability.

Blaber and his research team are creating artificial mutant proteins in their College of Medicine laboratory that mimic the human proteins used in angiogenic therapy, and with enhanced stability properties. So far, the mutant proteins engineered at the College of Medicine have exhibited potency in stimulating cell growth while simultaneously maintaining greater stability under conditions common to angiogenic therapy.

The work has enormous potential commercial applications and already has drawn the attention of private companies interested in the results Blabers lab has achieved and the intellectual properties his studies are generating.


'/>"/>

Contact: Doug Carlson
doug.carlson@med.fsu.edu
850-645-1255
Florida State University
Source:Eurekalert

Related medicine news :

1. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
2. Researchers Gain Insights Into On-Off Switch for Cells
3. Molecular science could further improve leukemia survival, say St. Jude researchers
4. Stanford researchers unmask proteins in telomerase, a substance that enables cancer
5. Recognizing outstanding young researchers
6. Researchers sharpen search for new marine medicines with novel techniques
7. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
8. Queensland researchers get the latest tools to fight cancer
9. Researchers find 1 in 6 women, 1 in 10 men at risk for Alzheimers disease in their lifetime
10. Researchers discover second depth-perception method in brain
11. Researchers study new drug and indications for heated chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: